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Background: The number of people with dementia is increasing, with huge challenges
for society and health-care systems. There are no disease-modifying therapies available.
There is, therefore, an urgent need to identify strategies to reduce the risk of developing
dementia. Anthocyanins are a class of compounds found in dark berries and fruits with
some effects that might reduce the risk for cognitive decline and the development of
dementia in older people.
Aim: This phase II three-center, randomized, 24-week, placebo-controlled study,
ongoing in Norway, aims to evaluate the safety, and efficacy of anthocyanins in modifying
key dementia-related mechanisms and maintain cognitive functioning in older people at
risk for dementia.
Methods: Participants (220 individuals aged 60–80 years) who meet the inclusion
criteria (either mild cognitive impairment or two or more cardiometabolic disorders)
are being enrolled in this study at three different centers in Norway. Participants are
block randomized to identically appearing capsules containing 80mg of naturally purified
anthocyanins or placebo 1:1. Dosage is 2 + 2 capsules per day for 24 weeks.
The primary outcome will be the quality of episodic memory score, a composite
measure from the extensively validated online cognitive test battery CogTrack®, which
is administered at baseline and monthly for the next 6 months. Secondary outcomes
include other major scores from CogTrack, as well as a range of neuroimaging and
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other biomarkers. Anthocyanin metabolites will be measured in blood and cerebrospinal
fluid. The change from baseline scores will be subject to a mixed model for repeated
measures analysis of covariance. The primary comparison will be the contrast (difference
in the least-square means) between active and placebo at the end of the study
(week 24). The primary study population will be a modified intention-to-treat population
(ClinicalTrials.gov, NCT03419039).
Discussion: This study aims to demonstrate whether there are beneficial effects
of purified anthocyanins on cognition and relevant biological functions in people at
increased risk for dementia. Forthcoming results may contribute to further improvement
of intervention strategies to prevent or delay the onset of dementia, including a potential
decision to take anthocyanins toward phase III trials.
Keywords: anthocyanins, mild cognitive impairment, dementia, randomized controlled trial, intervention
INTRODUCTION
Dementia has become a rising public health problem, and
the global socioeconomic burden of dementia is projected to
amplify (1, 2). Misfolding of proteins such as amyloid, tau, and
α-synuclein are key elements in the development of the most
common neurodegenerative dementias such as Alzheimer’s
disease (AD) and Lewy body dementia. According to the
most prominent hypothesis, the misfolding and aggregation of
amyloid peptides are the key initial elements in AD (3). However,
this is followed by secondary changes, including inflammation
(4) and oxidative stress (5), which also contribute to neuronal
dysfunction. Available treatments are only symptomatic,
affecting cholinergic, and glutaminergic neurotransmission with
modest clinical effect. There are no disease-modifying treatments
available, and several phase III trials with anti-amyloid agents
have failed (6) with some mixed but slightly more promising
results with phase-III aducanumab recently reported (7, 8).
Also, GV-971, a sodium oligomannate, from seaweed, has
received conditional approval by China’s National Medical
Product Administration as a new oral treatment for mild to
moderate AD (9). Notably, vascular risk factors, including
diabetes, hypertension, and hypercholesterolemia, are associated
with cerebrovascular disease, which is an important cause of
a cognitive decline in older people and also associated with
neurodegenerative diseases including AD (10). It is, therefore
important to explore alternative disease mechanisms, such as
inflammation (4), oxidative stress (5), and improvement of
microcirculation as potential novel treatment targets.
Furthermore, dysregulation of cerebral capillaries,
atherosclerosis, and endothelial changes also contribute to
the development of AD (11). The strongest genetic risk factor for
AD, the APOE e4 allele, is related to lipid metabolism (12), and
diabetes and insulin resistance are established risk factors for
AD (13). There are several studies (and reviews) that indicate a
Abbreviations: AD, Alzheimer’s disease; APOE e4, Apolipoprotein E e4; MCI,
mild cognitive impairment; CMD, cardiometabolic disorders; SP, study physician;
SRA, study research assistant; SUS, Stavanger University Hospital; Ahus, Akershus
University Hospital; CI, chief investigator.
decrease in dementia incidence (14, 15). Although this in itself
does not indicate that lifestyle can reduce dementia development,
it is possible dementia risk can be reduced by lifestyle changes
such as diet and physical activity (16).
Anthocyanins, a subclass of the flavonoids found in dark
berries and fruits, are among the dietary factors that may have
potentially positive effects on the pathogenesis of AD. Findings
from cell, animal, and human studies suggest that they have
antioxidant effects (17, 18), improve the blood lipid profile (19),
and also have anti-inflammatory effects (20). Also, anthocyanins
have been shown to increase flow-mediated dilatation (21–
23) and to cross the blood–brain barrier (24). Thus, these
substances have several effects relevant to protection against
key mechanisms leading to cognitive decline and dementia in
older people.
Interestingly, placebo-controlled studies have reported
improvement of memory functioning in older people with
memory problems or even dementia, after consumption of grape
juice (25), blueberry juice (26), and cherry juice (27) as the source
of anthocyanins. More recently, a randomized controlled trial
has concluded that food-based anthocyanidin consumption was
associated with a reduced risk of AD (28). However, previously
published studies have major methodological limitations,
including small sample sizes, short duration, and lack of
biomarkers (29).
It is therefore not clear if these promising preliminary findings
can be translated into clinically meaningful effects, that is,
reducing the rate of cognitive decline and risk of dementia.
Thus, they need to be substantiated in studies with a more
robust design.
We have therefore set up a randomized, 24-week, parallel-
group placebo-controlled three-center study: anthocyanins in
people at risk for dementia.
The aim is to explore the potential of anthocyanin capsules to
affect cognition in older people at risk for dementia favorably and
also a range of relevant neuroimaging and peripheral biomarkers
such as structural MRI, fluorodeoxyglucose positron emission
tomography, and inflammation, oxidative stress, lipids, and
other factors in the blood, cerebrospinal fluid (CSF), and gut
microbiome. Also, we measure the effects on microcirculation
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and endothelial elasticity. Our recent pilot study showed that the
anthocyanin capsules were well-tolerated (30).
METHODS
Trial Design
This is a phase II, three-center, randomized, 24-week placebo-
controlled trial enrolling 220 people living in three major cities
in Norway (Stavanger, Oslo, and Bergen).
Recruitment
Participants are being recruited from referrals to geriatric,
psychiatric, neurology, cardiology, or memory outpatient
clinics at two university hospitals and from advertisements in
newspapers, radio, and on various social media. Furthermore,
participants are recruited from the observational Dementia
Disease Initiation study (31) and by actively reaching out to
general practitioners in the areas.
Trial Population Inclusion and Exclusion
Criteria
Inclusion Criteria
People included in the study are those aged 60 years and older
having an increased risk for dementia, by having either mild
cognitive impairment (MCI) according to Winblad criteria (32)
with or without cardiometabolic disorders (CMD), or normal
cognition and ≥ 2 of the below stated CMDs known to be
associated with increased risk of cognitive impairment and
dementia (33–35): Stable cardiovascular disease, cerebrovascular
disease, and metabolic disorders such as hypercholesterolemia,
hypertension, or diabetes mellitus. The detailed inclusion criteria
are displayed in Table 1.
Exclusion Criteria
The exclusion criteria are dementia; relevant brain disease
such as Parkinson’s disease; or other brain diseases (except
AD or cerebrovascular disease), which according to the study
physician (SP) may cause cognitive decline; clinically significant
depression; a somatic disease that, according to the SP, might
affect cognitive functioning adversely; usage of anticoagulants;
and any use of the investigational product during the 12 months
before inclusion. A full list of the exclusion criteria is also
displayed in Table 1.
Investigational Product
We use Medox R© capsules, a standardized nutraceutical product
that contains naturally purified anthocyanins from bilberry
(Vaccinium myrtillus) and black currant (Ribes nigrum).
The content of each capsule is as follows: 50% Maltodextrin
Glucidex IT 19, 50% bilberry (V. myrtillus) and black currant
(R. nigrum) extract powder with 80-mg anthocyanin citrates
as the 3-O-rutinosides of cyanidin and delphinidin and the
3-O-b-galactopyranosides, 3-O-b-glucopyranosides, and 3-
O-a-arabinopyranosides of cyanidin, peonidin, delphinidin,
petunidin, and malvidin. Each capsule contains 80-mg
anthocyanins, and the dosage chosen is four capsules, 320
mg/day, whereas the identically appearing placebo capsules
contain 91% maltodextrin and 9% citric acid. This dosage
has been reported to be associated with relevant biological
alterations (19, 21, 30, 36) and to have good tolerability
(30). The manufacturer of Medox R©, MedPalett, is producing
Medox R© and identically appearing placebo capsules. The
participants are instructed to take two capsules twice daily
for 24 weeks, which are dispensed after randomization
in the study. The anthocyanins and placebo capsules are
identically packaged.
Trial Procedures and Rationale
Screening Procedures
All potential participants are prescreened for eligibility by a
telephone interview by study research assistants (SRAs) using a
prescreening questionnaire. Information about the trial is mailed
before the screening visit. Informed written consent is obtained
before enrollment into the trial according to Good Clinical
Practice principles. Participants are informed in the written
informed consent forms that they have the right to withdraw
from the study at any time without prejudice.
All eligible prescreened participants meet the SP and SRA
for collection of relevant clinical data that include medical and
psychiatric history, concomitant medications, both prescribed
medications and over-the-counter medications, demographics,
physical examination, and anthropometric measurements.
Various blood panels are being collected, including blood
count, metabolic panel, lipid panel, thyroid function tests,
and blood tests related to vitamin B12 and folate serum
level, and international normalized ratio for brief coagulation
status assessment. These blood tests are being performed
to exclude other medical illnesses, which may contribute to
cognitive decline.
Cognition is assessed with the Mini-Mental State Exam, the
Informant Questionnaire on Cognitive Decline in Elderly (37),
and the Clinical Dementia Rating scale (38). The Geriatric
Depression Scale (15 items) is also administered.
ECG, blood pressure, and pulse rate are recorded. Also,
photoplethysmography, cardio–ankle vascular index, and flow-
mediated dilation are performed in a subgroup.
Neuroimaging: Structural and functional brain MRI
(alternatively CT scan if MRI is contraindicated) and
fluorodeoxyglucose positron emission tomography imaging
are performed in a subgroup of participants, dependent on the
availability of relevant resources.
Venipuncture and lumbar puncture for collection, handling,
and storage of blood and CSF are performed according
to highly standardized operationalized procedures (see
Supplementary Material). Fecal and urine samples for
microbiome analyses are also collected.
Our main objectives for collecting neuroimaging and
biological samples are to test whether relevant changes associated
with dietary anthocyanin intake in participants with increased
risk of progressive cognitive decline can be detected, for example,
effects on the rate of loss of brain structure, cortical metabolic
activity, and on oxidative and inflammationmarkers in the blood,
CSF, and the microbiome.
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TABLE 1 | Principle inclusion and exclusion criteria for the trial.
Inclusion criteria Exclusion criteria
Age ≥ 60 years and < 80 years and no, or on stable central nervous system
medication for the past 3 months
AND
MCI according to Winblad criteria (32) (i.e., meeting the general MCI following criteria:
(a) the person is neither normal nor demented; (b) there is evidence of cognitive
deterioration shown by either objectively measured decline over time and/or
subjective report of decline by self and/or informant in conjunction with objective
cognitive deficits; and (c) activities of daily living are preserved, and complex
instrumental functions are either intact or minimally impaired)
OR
having ≥ 2 of the following conditions known to be associated with increased risk of
cognitive impairment and dementia:
➢ Stable cardiovascular disease defined as coronary artery disease seen on
angiogram
➢ Cerebrovascular disease according to MRI criteria (i.e., presence of Fazekas
score ≥2 points OR cerebral infarct (≥1 lesion) OR lacunar infarct (≥1 lesion)
OR lobar microbleed (≥1 lesion), as judged by a qualified neuroradiologist)
OR as visualized on CT scan for those having contraindications to MRI
➢ Hypercholesterolemia, operationalized as a history of hypercholesterolemia
and/or use of statin at baseline or serum cholesterol > 7 analyzed in
screening blood test
➢ Hypertension, operationalized as a previous diagnosis of arterial hypertension
and/or use of antihypertensive drugs
➢ Overweight (BMI > 25)
➢ Diabetes mellitus type 1
➢ Diabetes mellitus type 2 (i.e., history of and/or use of oral antidiabetic drugs
and/or HbA1c > 6.5%)
Any dementia (defined as CDR > 0.5)
Other known relevant brain disease such as Parkinson’s disease, normal
pressure hydrocephalus, and other diseases which according to the study
physician may cause cognitive decline
Diagnosis of clinical stroke last 5 years
Clinically significant depression, i.e., major depression or GDS-15 score ≥ 7
Unstable coronary heart disease
Heart failure in need of treatment
Systemic inflammatory diseases
Other serious disease with expected survival < 5 years
A somatic disease that might affect cognitive function adversely
Usage of heparin, warfarin, Clopidogrel, or Ticagrelor or Non-Vitamin K
antagonist Oral Anticoagulants
Any use of Medox® during the 12 months prior to inclusion
CAD, coronary artery disease; CDR, Clinician Dementia Rating scale; GDS, Geriatric Depression Scale; BMI, body mass index.
Second, we will investigate whether any biomarker changes
are associated with the various cognitive domains assessed with
the cognitive tests.
We will also perform subgroup analyses to explore whether
people with a CSF and/or MRI pattern typical of AD or
cerebrovascular disease respond differently to anthocyanins
compared with those without such changes. These biomarker
analyses will be tentative, as the study is not powered for
subgroup analyses but may be informative for planning a
potential phase III trial.
Baseline Assessment
At the baseline visit, any unplanned changes in medications since
the screening assessment are recorded, and any future changes
are discouraged if safe.
Participants are asked to maintain their lifestyle and habitual
diet during the intervention.
The capsules are then distributed to participants after
randomization (see later).
The participants will be trained in performing the CogTrack R©
System, an online set of cognitive tests with proven utility,
reliability, sensitivity, and validity (39), as well as reliable
sensitivity to change over time (40); (see later). The battery
of tests includes previously described tests, such as simple
reaction time, choice reaction time, digit vigilance, immediate
and delayed word recall and recognition, pattern separation,
spatial working memory, and numeric working memory (41).
The baseline test will be performed at home on two occasions
before taking the first study dose and then monthly for 6
months. Collection and registration of the cognitive data will
be performed securely online (39). Cognitive data are stored on
secure Amazon EC2 cloud servers with encryption in transit
(transport layer security) for data across services. Data will be
uploaded to Google Drive, into a folder where only authorized
persons from Wesnes Cognition can access using two-step
verification. Once the download is complete and confirmed by
the study team as received, the data will be removed from the
shared folder. A copy of the data remains on the Amazon EC2
databases. Participants are instructed to perform the test at the
same time of day on all occasions, usually in the morning,
and to ensure testing procedures are standardized as much
as possible (i.e., temperature, room, research associate, and
coffee intake).
Randomization, Allocation and Blinding
Participants are randomized to anthocyanins or placebo in a
1:1 ratio based on stratified block randomization. The strata are
made up of the combination of three treatment sites [Stavanger
University Hospital [SUS], Akershus University Hospital [Ahus],
Oslo, and Betanien Hospital, Bergen] and two recruitment
groups, that is, those who are recruited due to CMD criteria
only vs. those who are recruited due to cognitive criteria
with or without CMD criteria. Within each of the six strata,
the randomization is performed in blocks of varying sizes
(four or six) to ensure local balance and non-predictability
of allocation. The randomization lists with ID numbers and
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anonymous treatment arms (“A” and “B”) are produced by
the study statistician and sent to the production site, which
is instructed to do a random allocation (using a dice) to
specify which of A and B should be the intervention arm. The
capsules (anthocyanins and placebo) are produced according
to the randomization lists, marked with ID numbers, and
distributed to the participating centers. At the centers, the
participants are numbered consecutively at their inclusion in
the study. All study staff, participants, and the data analyst
remain blinded to the actual treatment given until data have
been analyzed.
Follow-Up Assessments
Participants are contacted by telephone after 4 weeks (for
discussion of safety and procedures) and seen in the clinic at
weeks 12 and 24 (final visit). Blood tests are also being collected
at weeks 12 and 24 (and weeks 2 and 6 for those performing
cardiovascular measurements). Lumbar puncture is performed at
baseline and again at week 24, and cardiovascular measurements
are performed at weeks 2, 6, 12, and 24. Feces and urine sampling
are collected at weeks 12 and 24. All the clinical visits are recorded
in the medical journal and the case report form. See the study
clinical assessment summary in Table 2 and the study flowchart
in Figure 1.
Upon the beginning of the study, a simplified version of
Table 1 is distributed to the participants to enable them to follow
the study phases.
Trial Medication Adherence and Monitoring
To be able to calculate medication adherence, the participants
will be instructed to write the time and date of first and last
capsule intake on the medicine package and to collect and return
the remaining capsules. These need to be brought along at the
next follow-up. The following formula will be used to calculate
medication adherence (42):
Number of capsules taken
Number of capsules the participant should have been taken
x100 = n %
The number of capsules the participant should have taken will
be calculated based on the number of days between the first and
last capsule intake. The remaining capsules in the package will be
subtracted from the total number of capsules to yield the number
of capsules taken. For example, if the participant should have
taken 360 capsules but have taken 324 capsules, the medication
adherence will be (324/360)× 100= 90%. Medication adherence
will be calculated between 0 and 12 weeks and from 12 to 24
weeks. Also, in the telephone interview, after 4 weeks, the intake
of capsules per protocol and any adverse effects will be noted.




Cognitive assessment: CogTrack R© is an online cognitive test
battery consisting of 10 subtests, which, based on factor analysis,
are combined into the following domains: attention, memory,
and cognitive speed. There are 14 different word lists, each
with 15 words, for the verbal memory test. The instructions
are presented visually at the start of each testing session and
also at the start of each task. In-task responses are made using
the right arrow on the keyboard in two tasks and the left and
right arrows in the other two. The participants are instructed
to rest their finger(s) lightly upon the key(s) throughout each
task. The speed and accuracy of every response are recorded. The
primary outcome measure will be the quality of episodic memory
combination of two accuracy scores from each of immediate
and delayed word recall, word and picture recognition (four
tasks in total), which has been shown to represent the overall
quality of episodic memory and to be sensitive to cognitive
changes, with negligible learning effects (39, 40). The battery is
completed online monthly at home, using different word-lists at
each occasion.
Secondary Outcome Measures
See test detail outlines in (39).
1) Secondary endpoints from the CogTrack System
will include:
a. attentional intensity index
b. sustained attention index
c. cognitive reaction time
d. attentional fluctuation index
e. quality of working memory
f. speed of memory retrieval.
Safety and Handling of Adverse Events
Anthocyanins are safe (30), and there are no serious adverse
effects to be expected. The study will nevertheless focus on safety,
as explained later.
Recording Adverse Events
At each study visit, the participants are proactively asked about
the occurrence of any adverse experiences, particularly about
any abnormal bleeding since his/her last visit. The site SRA
and SP will also assess adverse events by assessment of clinical
and laboratory features. All adverse events, whether observed
by the SP or elicited from or volunteered by the participant,
will be documented. Blood is analyzed for safety with routine
clinical analyses (liver, kidney, hematology, and international
normalized ratio) at weeks 12 and 24. The electrocardiogram
is taken at study inclusion and at week 24. Telephone and e-
mail addresses of the SRA and SP are available to facilitate easy
communication about possible adverse events. If dementia or
other new medical conditions are detected during the screening
process, this information is forwarded to the general practitioner
if the participant agrees. If deemed necessary, action may also be
taken by the SP.
Serious Adverse Events
Any serious adverse events during the study are recorded, and
actions from the SRA and SP are taken as needed. The chief
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− Dispense trial capsules x x
− Concomitant medications x x x x x
− Heart rate
− blood pressure









− Cardiovascular measurements x x x x x
− Blood sampling x x x x x









− CogTrack training X




− Compliance check (Collection
of bottles/blisters)
x x
− Adverse event monitoring x x x
− Question about change
in lifestyle
x x x
BMI, body mass index; ECG, electrocardiogram; FDG-PET, fluorodeoxyglucose positron emission tomography; CAVI, cardio–ankle vascular index; FMD, flow-mediated dilation; PPG,
photoplethysmography; MMSE, Mini-Mental State Examination; CDR, Clinician Dementia Rating scale; IQCODE, The Informant Questionnaire on Cognitive Decline in the Elderly; GDS,
Geriatric Depression Scale.
investigator (CI) is to be notified within 24 h of investigator
awareness of the event.
Emergency Unblinding
Given the safety profile of anthocyanins that have been reported
(30, 43), we expect the need for emergency unblinding to be
extremely rare. Nevertheless, we have the following procedure in
case emergency unblinding is required:
If unblinding is deemed to be necessary for the event of
significant concerns regarding participant safety, the CI will be
notified immediately by the SP. If the CI considers emergency
unblinding necessary, a request will be directed to appointed
personnel at the MedPalett. The requested information will be
transmitted to the requesting party. The CI will coordinate
the process.
The actual allocation must not be disclosed to the
participant or other trial personnel since the trial is
placebo controlled-double-blind. Emergency unblinding
should not necessarily be a reason for trial drug
discontinuation. Details of any emergency unblinding shall be
well-documented.
Governance and Monitoring
The sponsor of the study is SUS. The clinical research
group includes Ph.D. candidates, postdocs, and clinicians
from the three different centers. A trial manager is in
day-to-day charge of the trial and responsible for trial
documentation, supporting the centers to recruit promptly,
monitoring compliance with the protocol, and organizing
meetings of the trial management group. This group includes
CI, the local principal investigators, an external expert, and the
trial manager. A decision-making group, with members from the
clinical research group, will discuss relevant medical or ethical
issues via e-mail.
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FIGURE 1 | Flowchart of the trial. SUS, Stavanger University Hospital; Ahus, Akershus University Hospital; BH, Betanien Hospital, CMD, cardiometabolic disorders;
MCI, mild cognitive impairment; FDG-PET, fluorodeoxyglucose (FDG) positron emission tomography (PET); CAVI, cardio–ankle vascular index; FMD, flow-mediated
dilation; PPG, photoplethysmography; MMSE, Mini-Mental State Examination; CDR, Clinician Dementia Rating scale; IQCODE, The Informant Questionnaire on
Cognitive Decline in the Elderly; GDS, Geriatric Depression Scale. *cardiovascular measurements are only performed at SUS and Ahus. *FDG-PET scan is only
performed at SUS.
Data Storage
All parties will ensure the protection of subject personal data, and
subject names or other identifiable data are not included in any
reports, publications, or other disclosures, except where required
by law. Data are stored securely, both on paper, on password-
protected computers at the site, and encrypted online, at SUS
with locked doors and shelves, with access only to dedicated
study personnel.
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Statistical Considerations
Sample Size Calculations
The sample size calculations are based on published data on
CogTrack (40). We will assume a Cohen’s d effect size of 0.4,
two-tailed testing at p < 0.05, at 80% power, which is considered
to be a clinically relevant effect. A sample size of 110 patients
per arm is required, allowing for ∼10% dropout. Analyses will
be adjusted for baseline scores for each test. A priori subgroup
analyses are planned, including separate analyses of those with
MCI vs. normal cognition, old vs. middle-aged (defined as above
or below median age), participants with and without CMD, and
those with normal and those with abnormal CSF AD markers,
although the study is not powered for these analyses.
Planned Statistical Analyses
The primary analysis will be the comparison between the active
and placebo groups on CogTrack quality of memory domain
score change during follow-up. The primary study population
will be a modified intention-to-treat population, that is, all
participants having ingested at least one capsule and with at least
one follow-up assessment.
Summary statistics (n, mean, standard deviation, and
minimum and maximum scores) will be calculated by treatment
arm for the data at each testing session, and, additionally, for
the change from baseline scores. A mixed model for repeated
measures ANCOVAwill analyze the change from baseline scores.
The primary comparison will be the contrast (difference in least-
square means) between active and placebo at the end of the study
(week 24) (44). A detailed statistical analysis plan will be finalized
before the unblinding of data.
Trial Status
The study started the recruitment of participants in April 2018.
We are expecting to reach the recruitment target in summer 2020
and expect completion of the study during 2020.
DISCUSSION
Out of 236 participants who have been assessed for eligibility, 50
participants were excluded (49 not meeting the inclusion criteria,
and one declined to participate). As of the end of February 2020,
181 participants have been randomized; 123 in the CMD group
and 58 in the MCI group. Among the strengths of this trial
is the relatively large sample size, making it one of the largest
anthocyanin trials and sufficiently powered to detect a medium
effect of anthocyanins on primary cognitive outcome measures.
The use of web-based cognitive assessment enables frequent
testing without learning effects, which is increasing the statistical
power. The comprehensive acquisition of biomarkers allows for
a detailed mechanistic study of anthocyanin effects. Finally, the
collection of blood and CSF for anthocyanin metabolite analyses
allows for analysis of dose effects. However, some limitations of
this trial are the lack of dietary records and not giving specific
dietary instructions concerning the intake of anthocyanin-rich
foods. However, participants are asked to maintain their habitual
diet during the intervention period. Of note, applying any dietary
restrictions in a long-term trial lasting 24 weeks might challenge








Men, n (%) 47 (55%) 33 (55%) 14 (54%)
Age in years 68 (65, 74) 68 (64, 74) 69 (66, 76)
Education
in years
14 (11, 16) 14 (11, 16) 14 (12, 17)
MMSE
score




3 (2, 5) 3 (2, 5) 2 (1, 4)
Data are presented as median (interquartile range, IQR) unless otherwise specified.
SUS, Stavanger University Hospital; CMD, Cardiometabolic disorders; MCI, mild cognitive
impairment; MMSE, Mini-Mental Status Examination.
participant’s compliance. Importantly, the study has a washout
period of 12months after anyMedox R© intake to provide a period
of abstinence from the interventional product.
The 6 months’ trial duration is similar to previous trials
with cholinesterase inhibitors and expected to be sufficiently
long to detect differences in terms of symptoms but might
be too short to detect disease-modifying effects on the risk to
progress to dementia or biology. The number of participants
with MCI is lower than the group with CMD, resulting in
reduced power for sub-analysis in this group. The participants
are largely ethnic Norwegian, that is, Caucasians, with relatively
high socioeconomic status and educational level. Thus, the
findings might not be immediately relevant to other populations.
Some initial characteristics based on the first 86 randomized
participants at SUS (pre-intervention) are displayed in Table 3.
Finally, anthocyanins might have biological effects, for example,
stool color change or constipation, with the risk for participants
or research staff to become unblinded. However, there might be
many possible explanations for any such changes unrelated to
the study.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by The Norwegian regional ethics committee
(2017/374). The patients/participants provided their written
informed consent to participate in this study. The trial has been
registered at: http://www.clinicaltrials.gov/, NCT03419039.
SERVICE USER INVOLVEMENT
The valuable feedback provided by our participants in our
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